Shots:

• The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms
• The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities
• Boehringer Ingelheim focuses to accelerate the delivery of first-in-class immuno-oncology therapies to patients across the globe

 ­ Ref: Businesswire | Image: Labor Merk